Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22
Bryan A, Earnshaw SR, McDade C, Ines M, Micallef C, Enoch DA. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected Aspergillus infection. Poster presented at the 2021 Virtual 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); July 9, 2021.
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021
Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.
Barnes R, Earnshaw SR, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade CL. Economic comparison of empirical versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infection. Poster presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 2013.
Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012 Feb 1;6:155-64.
Earnshaw SR, McDade CL, Zanotti G, Farkouh R, Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent pneumococcal conjugate vaccine compared with 2+1 dosing of 10-valent conjugate vaccine in preventing pneumococcal disease in Canada. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A275.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the 9th Canadian Immunization Conference; December 2010. Previously presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Roussy JP, Kwan H, Earnshaw SR, Farkouh RA, Hwang S, Strutton D. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine compared with 10-valent vaccine in preventing pneumococcal infections in Quebec. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2010.
Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Strutton DR, Kuchenbecker U, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination on costs and outcomes in Germany and the United States. Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009.
Stoykova B, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in the United Kingdom (UK). Poster presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases; June 2009. Brussels, Belgium.
Rivera R, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination versus 7-valent pneumococcoal conjugate vaccination in Mexico. Poster presented at el Pediátrica XIII Congreso Latinoamericano de Infectología Pediátrica; May 2009.
Hernandez JD, Strutton D, Hwang S, Earnshaw SR, Farkouh RA. Impact of 13-valent pneumococcal conjugate vaccination compared to 7-valent pneumococcal conjugate vaccination in Colombia. Poster presented at La Sociedad Latinoamericana de Infectología Pediátrica XIII Congreso Latinoamericano de Infectología; May 2009.
Farkouh RA, Earnshaw SR, Watson ME, Maroudos P. Short-term cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir. Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Disease Society of America 46th Annual Meeting; October 2008.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Farkouh RA, Earnshaw SR, Kauf TL, Watson ME, Maroudas P. Cost-effectiveness of hla*b-5701 testing prior to initiation of abacavir sulfate. Poster presented at the 17th International AIDS Conference; August 2008.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Earnshaw SR, Graham CN, Gasper S. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis. Poster presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 2007.
Earnshaw SR, Hicks K, Richter A, Honeycutt A. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci. 2007 Sep 1;10(3):239-52.
Earnshaw SR, Sikirica V, Roskell NS, Shannon PR, Beard S, Schein J, Doshi D, Janagap C. Economic analysis of short-course levofloxacin versus amoxicillin/clavulanate in treating acute bacterial exacerbations of chronic bronchitis. Poster presented at the Academy of Managed Care Pharmacy 19th Annual Meeting Showcase; April 14, 2007.
Shearer A, Gazzard B, Graham CN, Davis EA, Mauskopf J, Kitahata M, Saag MS, Earnshaw SR. Simulation modeling of adherence and resistance on long-term outcomes in HIV. Poster presented at the Infectious Disease Society of America 44th Annual Meeting; October 15, 2006.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.
Earnshaw SR, Wirth K, Hicks KA. Pilot test of the RTI HIV prevention resource allocation tool. Presented at the Florida Department of Health; August 2003.
Hicks KA, Honeycutt AA, Earnshaw SR, Richter A. A tool for comparing allocations of HIV prevention resources. Presented at the National HIV Prevention Conference; August 2003.
Earnshaw SR, Richter A, Hicks KA, Honeycutt A. The allocation of HIV prevention funds. Poster presented at the 2003 ISPOR 8th Annual International Meeting; May 2003.
Hicks KA, Honeycutt A, Earnshaw SR, Richter A. Models for the efficient allocation of HIV prevention resources. Presented at the Community Planning Leadership Summit for HIV Prevention; March 2003.
Earnshaw SR, Richter A, Hicks K, Honeycutt A. The allocation of HIV prevention funds. Value Health. 2003 Jan 1;6(3):254.
Honeycutt AA, Richter A, Earnshaw SR, Hicks KA. A model for allocating HIV prevention resources. Poster presented at the CDC's "Practical Use of CEA" 01158 Grantee Meeting; December 2002.